Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building Digital Platforms To Bridge Diabetes Care Gaps

Executive Summary

Are digital solutions the missing link for diabetes care? Glooko and Omada Health think so. Both have developed device-integrating platforms to help patients manage their condition.

You may also be interested in...



Digital Health Roundup: Solutions For Heart, Loneliness; Diabetes Talks; Post-Roe Legal Advice

In this month’s Digital Health roundup, Medtech Insight’s Barnaby Pickering discusses DeHealth, which developed a platform built on cryptocurrency, and executive interviews with Glooko and Omada Health about their diabetes platforms. Marion Webb will highlight a conversation with Nixon Gwilt Law attorney Bethany Corbin about key steps developers of period-tracking apps can take to ensure that sensitive health data remains safe and private. Reed Miller discusses Braidio’s health information platform and Pyx Health’s hybrid solution for loneliness.

ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises

The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.

Exec Chat: Glooko CEO Talks Differentiation, Collaboration And The Future Of Digital Diabetes Solutions

Medtech Insight talked to Russ Johannesson about Glooko’s connected diabetes care strategy, including its recent agreement with John Hopkins HealthCare Solutions and acquisition of Diabnext, a French competitor.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel